FDA MDUFA VI Fees: Proposed Increases for Overseas Manufacturers

The US FDA is considering higher user fees for overseas medical device manufacturers under the proposed MDUFA VI agreement for fiscal years 2028-2032. This episode breaks down the key takeaways from the FDA's public meeting on August 10, 2026, including the agency's rationale for the increase, the potential financial impact on non-US firms, and the critical deadlines for submitting public feedback before the proposal goes to Congress in January 2027. Key Questions: - What is MDUFA VI and why is it important for medical device manufacturers? - What specific fee changes are being proposed for overseas facilities? - What was the FDA's rationale for the proposed fee increase? - What are the key dates and deadlines for providing public feedback? - How could these changes impact your company's budget and market access strategy for the US? - What steps should your regulatory team take now to prepare? - Why are foreign establishment inspection costs a central part of this discussion? - When is the final MDUFA VI package expected to be sent to Congress? Sources: - https://www.medtechdive.com/news/mdufa-vi-fda-industry-patient-device-fees/723118/ How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes like the FDA's MDUFA VI proposal. We provide strategic guidance on US market access, help you analyze the financial impact of new fee structures, and assist in preparing technical dossiers and submissions. Our combination of local US regulatory expertise and advanced AI technology streamlines the path to market, ensuring you can adapt to new requirements efficiently. Whether you're a startup or a global enterprise, we can help you maintain and expand your presence in the US market. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.